Jun Huang

Jun Huang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
YWYang Wang
Yang Wang
YZYu Zhang
Yu Zhang
JHJun Huang
Jun Huang
XCXiaoyan Chen
Xiaoyan Chen
XGXiang Gu
Xiang Gu
YGYang Guo-Yuan
Yang Guo-Yuan
The relationship between circulating microRNA-223 and pathogenesis of acute ischemic stroke is unknown. Here we investigated the roles and possible targets of circulating microRNA-223 in human ischemic stroke within the first 72 hours.

16 March 2025 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
BZBing Zhao
Bing Zhao
WSWenwu Sun
Wenwu Sun
YWYihui Wang
Yihui Wang
LMLi Ma
Li Ma
MGMenglu Gui
Menglu Gui
EMEnqiang Mao
Enqiang Mao
The aim of this study was to investigate whether high-dose intravenous vitamin C (HDIVC) could decrease the mortality rate within 28 days among patients moderately severe acute pancreatitis (MSAP) and severe acute pancreatitis (SAP). In this randomized, placebo-controlled trial, patients diagnosed with predicted MSAP or SAP within 72 h of symptom onset were enrolled to receive either a vitamin C infusion (200 mg/kg/24 h) or a matched placebo for 7 days. The primary outcome was 28-day mortality. 212 adults including 155 MSAP and 57 SAP were enrolled from September 2019 to June 2023. The trial was terminated prematurely due to a lower than expected 28-day mortality rate which showed no difference between the HDIVC and Control group (3/109 vs. 4/103, unadjusted OR: 0.70, 95% CI, 0.15–3.21, p = 0.647). Among patients with MSAP, the HDIVC group exhibited a more pronounced reduction in C-reactive protein levels compared to the Control group (Day0 to Day3, median 72 mg/L vs. 46 mg/L, p = 0.003; Day0 to Day7, median 168 mg/L vs. 121 mg/L, p = 0.013); The volume of fluid retention was lower in the HDIVC group compared to the Control group (Day0-Day1, median 676.5 ml vs. 1130 ml, P = 0.04; Day0-Day2, median 511 ml vs. 1290 ml, P = 0.02; Day0-Day3, median 692 ml vs. 1534 ml, P = 0.04). The APACHE II scores reduction from Day0 to Day7 was significantly greater in the HDIVC group in APACHE II scores (median change of 3 vs. 2, P = 0.01). No significant difference was observed among patients with SAP. HDIVC did not significantly reduce 28-day mortality in MSAP and SAP patients. While it showed potential benefits in reducing CRP, fluid retention, and APACHE II scores in MSAP patients, these effects may not be directly related to the study drug, and no similar changes were observed in SAP patients. ChiCTR.org.cn, ChiCTR1900022022. Registered March 21 2019, https//www.chictr.org.cn/showproj.html?proj=37,106 .

6 August 2026 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
BZBing Zhao
Bing Zhao
XYXianxian Yu
Xianxian Yu
HZHaibo Zhang
Haibo Zhang
MYMeiling Yu
Meiling Yu
WSWenwu Sun
Wenwu Sun
EMEnqiang Mao
Enqiang Mao
Background: The global incidence of severe acute pancreatitis (SAP) is increasing, yet mortality rates remain persistently high. Novel therapeutic approaches are urgently needed to improve outcomes. The aim of this study is to evaluate the efficacy of high-dose intravenous vitamin C in improving organ support-free days within the first 14 days and other clinical outcomes in patients with SAP. Method: This is a prospective, randomized, double-blind, multicenter clinical trial. Participants will be stratified and randomly assigned to either the HDIVC group or the control group. Data will be analyzed using SAS 9.4 with two-sided tests and a significance threshold of p < 0.05. This study will be conduct at eight hospitals in China, including Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai General Hospital, Changhai Hospital, Sichuan Provincial People’s Hospital, Chongqing Daping Hospital, The Second People’s Hospital of Chengdu, Guanghan People’s Hospital and Chongqing Emergency Medical Center. Eligible patients are adults (age ≥ 18 years) diagnosed with severe acute pancreatitis according to 2012 Atlanta classification within 7 days of onset. HDIVC (500 mg/kg, 2 g/h) or placebo (normal saline) will be administered via central vein for 7 days. The primary outcome is organ support-free days within the first 14 days. Secondary outcomes include ICU all-cause mortality, changes in inflammatory biomarkers, and organ failure scores. Discussion: If proven effective, the results of this trial could establish high-dose intravenous vitamin C as a cost-effective adjunctive therapy to improve survival in patients with severe acute pancreatitis and potentially inform future clinical practice guidelines. Clinical trial registration: ClinicalTrials.gov , identifier NCT06897384.